Filing Details

Accession Number:
0001209191-22-054201
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-10-20 17:25:38
Reporting Period:
2022-10-18
Accepted Time:
2022-10-20 17:25:38
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1595585 Tricida Inc. TCDA Pharmaceutical Preparations (2834) 463372526
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1602263 Vhcp Management Ii, Llc C/O Venrock
3340 Hillview Avenue
Palo Alto CA 94304
No No Yes No
1602264 Venrock Healthcare Capital Partners Ii, L.p. C/O Venrock
3340 Hillview Avenue
Palo Alto CA 94304
No No Yes No
1615979 Y Bong Koh C/O Venrock
3340 Hillview Avenue
Palo Alto CA 94304
No No Yes No
1615983 Vhcp Co-Investment Holdings Ii, Llc C/O Venrock
3340 Hillview Avenue
Palo Alto CA 94304
No No Yes No
1698082 P Nimish Shah C/O Venrock
3340 Hillview Avenue
Palo Alto CA 94304
No No Yes No
1738048 Venrock Healthcare Capital Partners Iii, L.p. C/O Venrock
3340 Hillview Avenue
Palo Alto CA 94304
No No Yes No
1738053 Vhcp Management Iii, Llc C/O Venrock
3340 Hillview Avenue
Palo Alto CA 94304
No No Yes No
1750761 Vhcp Co-Investment Holdings Iii, Llc C/O Venrock
3340 Hillview Avenue
Palo Alto CA 94304
No No Yes No
1808512 Venrock Healthcare Capital Partners Eg, L.p. C/O Venrock
3340 Hillview Avenue
Palo Alto CA 94304
No No Yes No
1808518 Vhcp Management Eg, Llc C/O Venrock
3340 Hillview Avenue
Palo Alto CA 94304
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-10-18 40,400 $11.98 9,891,480 No 4 P Indirect By Funds
Common Stock Acquisiton 2022-10-19 241,366 $10.29 10,132,846 No 4 P Indirect By Funds
Common Stock Acquisiton 2022-10-19 70,100 $11.25 10,202,946 No 4 P Indirect By Funds
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By Funds
No 4 P Indirect By Funds
No 4 P Indirect By Funds
Footnotes
  1. Consists of (i) 10,621 shares purchased by Venrock Healthcare Capital Partners III, L.P. ("VHCP III"), (ii) 1,062 shares purchased by VHCP Co-Investment Holdings III, LLC ("VHCP Co-3") and (iii) 28,717 shares purchased by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG").
  2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.97 to $12.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
  3. VHCP Management II, LLC ("VHCPM II") is the general partner of Venrock Healthcare Capital Partners II, L.P. ("VHCP II") and the manager of VHCP Co-Investment Holdings II, LLC ("VHCP Co-2"). VHCP Management III, LLC ("VHCPM III") is the general partner of VHCP III and the manager of VHCP Co-3. VHCP Management EG, LLC ("VHCPM EG") is the general partner of VHCP EG. Messrs. Shah and Koh are the voting members of VHCPM II, VHCPM III and VHCPM EG. Each of VHCPM II, VHCPM III, VHCPM EG, Shah and Koh expressly disclaims beneficial ownership over all shares held by VHCP II, VHCP Co-2, VHCP III, VHCP Co-3 and VHCP EG except to the extent of its or his indirect pecuniary interest therein.
  4. The shares purchased on October 19, 2022 consist of (i) 81,884 shares purchased by VHCP III, (ii) 8,192 shares purchased by VHCP Co-3 and (iii) 221,390 shares purchased by VHCP EG.
  5. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.01 to $11.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
  6. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.05 to $11.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.